Congenital hyperinsulinusm is rare disease characterized high secretion of insulin by pancreatic beta cells leading to the development of hypoglycemia. Persistent and transient forms of hyperinsulinism are distinguished. Transient hyperinsulinism are the most common cause of severe hypoglycemia in newborns. The etiology of this disease is not known. There are risk factors for the development of transient hyperinsulinism: asphyxia at birth, prematurity, maternal diabetes, low or large weight by gestation. Hypoglycemia with hyperinsulinism is severe. Therefore, early diagnosis and therapy especially during the neonatal period, are necessary.The article describes 3 clinical cases of transient hyperinsulinism in children with different gestational age and concomitant pathology. All children recevied insulinostatic therapy with diazoxide with a positive effect: euglycemia without glucose requirement . In all children, therapy was completed subsequently. At the time of publication of the article, the physical and psychomotor development of children is normal.
The uncontrolled course of bronchial asthma (BA) in children and insufficient efficacy of standard therapy regimens may be due to underestimated infectious factors. The objective: to study specific parameters of the course and treatment of mycoplasma infection, improve monitoring over BA therapy in children of the tender and preschool age. Subjects and methods. 320 children with BA in the age from 1 to 7 years old were followed up. In this work, Mycoplasma pneumoniae (FH), Mycoplasma hominis (H-34), Ureaplasma urealyticum (serotype 8), Mycoplasma fermentans (PG18) and Mycoplasma arthritidis (PG6) were used, they were cultured on a liquid medium for cultivation of mycoplasmas and ureaplasmas. To isolate CIC from blood serum samples, we used the method of precipitation with 3.5% polyethylene glycol (PEG, 6000 Da), hemagglutination assays and IFA were used to identify mycoplasma antigens, mycoplasma DNA was detected by PCR with InterLabService diagnostic kits. The data of 47 patients with prolonged mycoplasma antigenemia were assessed at the baseline and in 1.5-3 months after the treatment course of azithromycin.Results. 320 blood serum samples from children with BA were tested, and the detection rate by hemagglutination assays of M. pneumoniae antigens was 60.9%, M. hominis – 43.4%, U. urealyticum – 44.8%, M. arthritidis – 29.7%, M. fermentrans – 45.3%. The assessment of relationship between of M. pneumoniae, M. hominis and asthma exacerbation showed that antigens of M. pneumoniae and M. hominis were found in 216 children (single or associated). After treatment with azithromycin, the frequency of BA exacerbations within 3 months decreased by 2.4 times, as well as there was a reduction in the number of samples positive for antigens and DNA of mycoplasma in a free state and within CIC. The persistence of antigens, DNA of M. pneumoniae and M. hominis before treatment of 47 children was 80.9 and 66.0% of cases, after treatment with azithromycin – 31.9 and 25.5% of cases, respectively (p < 0.001). Within CIC isolated from the blood serum of patients, antigens to M. pneumoniae and M. hominis before treatment were detected by IFA in 63.8 and 70.2% of children, after treatment – in 31.9 and 23.4%, respectively. p < 0.001. In blood samples, DNA of M. pneumoniae and M. hominis was detected by PCR before treatment in 8.5 and 34.0%; after treatment in 6.4% (p = 0.318) and 19.1% of cases, respectively (p = 0.009), and within CIC isolated from blood serum, in 27.7 and 48.9% of cases before treatment and 8.5 and 34.0% after it, respectively (p = 0.009).
Start of the CFTR modulating therapy is an important and promising step towards better treatments for all cystic fibrosis (CF) patients. Therapy with CFTR potentiator Ivacaftor resulted in dramatic improvements in CFTR function in patients with G551D mutation, later it was prescribed for patients with another 9 gating mutations. We present a case of successful treatment of a CF patient with G461E/N1303К genotype. We have suggested that due to gating mutation G461E, the patient may profit from the treatment with ivacaftor. After six months of treatment, sweat chlorides concentration decreased from 93 mmol/l to normal 50 mmol/l, respiratory function (FEV1) increased from1.44 L(48%pred) to2.0 L(67%pred). The clinical course of the disease has changed significantly. The patient became stable; symptoms of chronic bronchitis diminished. There are other gating mutations in the Russian National Registry that may profit from treatment with ivacaftor.
Supplemental PEG tube feeding improves the nutritional status (BMI, body weight) of patients with very severe CF.
The major risk factor for death in cystic fibrosis (CF) is a progressive lung injury; however, low nutritional status (NS) remains an important and underestimated problem in the management of these patients. The NS of a patient with CF is impaired by many factors, such as chronic malabsorption, pancreatic failure, chronic inflammation, and recurrent pulmonary infection - they all lead to higher energy demand in the presence of lower intake of nutrients. The NS of those with CF plays an important role in maintaining lung function. The patients with higher NS have longer life expectancies. According to the Russian National Registry, both pediatric and adult patients with CF have shorter life expectancies. The article discusses various nutritional support regimens and their impact on lung function parameters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.